Randomization is now so central to clinical trials that it can be easy to forget what problem it was created to solve.

Before randomized allocation became a standard part of trial design, treatment assignment could be influenced by judgment, preference, sequence, availability, or expectation. Even when decisions were made carefully, the possibility of bias was difficult to remove. If investigators knew or could predict the next treatment assignment, the comparison between groups could be affected before the treatment was ever given (Chalmers, 2011; Yoshioka, 1998).

That is why randomization became such an important turning point. It was not only a statistical idea. It was a way to protect the question the trial was trying to answer.

The streptomycin trial

One of the landmark examples is the Medical Research Council’s streptomycin trial in pulmonary tuberculosis, planned in 1946 and published in 1948 (Medical Research Council, 1948).

At the time, tuberculosis was a major public health threat, and streptomycin was a promising new treatment. The question was urgent and practical: did streptomycin improve outcomes for patients with pulmonary tuberculosis?

Answering that question required more than interest in a new therapy. It required a comparison that could be trusted.

The trial assigned patients either to streptomycin plus bed rest or to bed rest alone. The important methodological step was that allocation was randomized and concealed from those enrolling patients. In practical terms, this meant the next treatment assignment could not be known in advance (Chalmers, 2011; Medical Research Council, 1948).

That mattered because foreknowledge can change behavior.

A patient who appears more severely ill might be entered differently if the investigator knows what treatment is next. A patient who looks more likely to benefit might be handled differently. Even with good intentions, judgement can influence who enters which group.

The MRC streptomycin trial helped show that the assignment process itself needed protection. The trial was not only testing a treatment. It was demonstrating a more disciplined way to protect the question being asked.

Why this changed trial methodology

The deeper lesson from the streptomycin trial is not simply that randomization was used. It is that clinical trials needed a process that could reduce bias before treatment began.

This changed the operational mindset of trial design.

A trial was no longer only about the treatment, the endpoint, and the patient population. It was also about the method of assignment. Who knows what? When is treatment assigned? Can the next assignment be predicted? Is the comparison protected before the patient receives treatment?

Those questions became part of how evidence was made reliable.

Randomization helped create comparable groups. Concealment helped protect the moment of enrollment. Together, they strengthened confidence that trial results reflected the treatment being studied, rather than the decisions made around patient entry (Chalmers, 2011; Yoshioka, 1998).

That principle still sits underneath modern clinical trial execution.

Randomization was never just a list

It can be easy to think of randomization as a list: patient one goes here, patient two goes there, and the trial moves forward.

That misses the point.

Randomization is a decision point that protects the trial. It supports the comparison between groups. It protects the blind. It helps reduce bias. It creates a record of how the assignment happened and why it can be trusted.

In earlier trials, that control point may have been relatively contained. In modern trials, randomization often sits inside a much more connected operating model.

A study may include stratification, variable blocks, multiple treatment arms, dose levels, cohorts, regions, or patient populations. Assignment may depend on country requirements, cohort status, patient eligibility, prior treatment, biomarker information, or treatment availability. Once randomization occurs, it may also trigger dispensing, kit assignment, inventory updates, reporting outputs, and downstream data flows.

The principle remains the same. Treatment assignment needs to be controlled. What has changed is how much now connects to that assignment.

Where RTSM enters the story

RTSM did not create the need for randomization control. It grew from the same operational requirement: the study needs a reliable, traceable way to execute what the protocol requires.

In a modern trial, assignment cannot be separated from the wider study environment. The system may need to protect the randomisation logic, maintain the blind, guide the site through the correct workflow, connect assignment to dispensing, update inventory, support resupply, and preserve an audit trail.

This is why RTSM has become more than a mechanism for assigning treatment.

It is part of the operational layer that helps the study run according to its design.

That does not mean complexity should be pushed onto the site. The more complex the trial, the more important it becomes for the system to make the right action clear. Site users should not have to interpret every layer of allocation logic, supply availability, cohort status, or protocol dependency in real time.

The system should carry that logic behind the scenes.

The Lesson That Still Holds

The MRC streptomycin trial belongs to a very different era of clinical research, but the lesson still applies.

Evidence depends on trust. Trust depends on control. And control depends on a process that protects the integrity of the trial before, during, and after treatment assignment.

In modern trials, the scope of that control has expanded.

Randomization may now sit alongside adaptive design, dose movement, biomarker-led eligibility, constrained supply, regional variation, and live protocol change. The original need remains, but the operational environment is much more demanding.

That is why this historical moment still matters.

Randomization needed control because evidence needed trust.

Today, RTSM carries that discipline into a more complex trial environment, helping translate protocol intent into controlled execution.

References

Chalmers, I. (2011). Why the 1948 MRC trial of streptomycin used treatment allocation based on random numbers. Journal of the Royal Society of Medicine, 104(9), 383-386. https://doi.org/10.1258/jrsm.2011.11k023

Medical Research Council. (1948). Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation. British Medical Journal, 2(4582), 769-782.

Yoshioka, A. (1998). Use of randomisation in the Medical Research Council’s clinical trial of streptomycin in pulmonary tuberculosis in the 1940s. BMJ, 317(7167), 1220-1223.